← Back to Search

PsA Screening Questionnaire for Psoriatic Arthritis

N/A

Recruiting

Led By Jessica Walsh, M.D.

Research Sponsored by Jessica Walsh

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Be age 18 or older

Have an International Classification of Diseases (ICD) code diagnosis of psoriasis but without a confirmed diagnosis of Psoriatic Arthritis prior to study initiation

Must not have

Have psoriasis and a confirmed diagnosis of psoriatic arthritis made or confirmed by a rheumatologist

Timeline

Screening 3 weeks

Treatment Varies

Follow Up 6 months

Awards & highlights

No Placebo-Only Group

Summary

This trial will aim to develop a screening questionnaire that can be used by psoriasis patients to detect early signs of Psoriatic Arthritis, without needing to involve dermatologists.

Who is the study for?

This trial is for adults over 18 with a diagnosis of psoriasis who haven't been diagnosed with Psoriatic Arthritis. Participants should live close to the study site and have not started any treatment for Psoriatic Arthritis.

What is being tested?

The study is testing a new way to find out if people with psoriasis might also have Psoriatic Arthritis using a questionnaire that patients can fill out on their own, without needing to visit doctors' offices.

What are the potential side effects?

Since this trial involves completing a questionnaire rather than taking medication or undergoing medical procedures, there are no direct physical side effects associated with participating in this study.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Select...

I am 18 years old or older.

Select...

I have been diagnosed with psoriasis but not with psoriatic arthritis.

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:

Select...

I have psoriasis and a rheumatologist confirmed I also have psoriatic arthritis.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ 6 months

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~6 months

This trial's timeline: 3 weeks for screening, Varies for treatment, and 6 months for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.

Primary study objectives

Percentage of patients with a new PsA diagnosis

Symptom duration

Secondary study objectives

Percentage of patients who complete a rheumatologic evaluation

Physical function level in PsA

PsA Activity by Dactilitis Count

+6 more

Awards & Highlights

No Placebo-Only Group

All patients enrolled in this study will receive some form of active treatment.

Trial Design

3Treatment groups

Experimental Treatment

Active Control

Group I: Intervention with Standard of Care ReferralExperimental Treatment1 Intervention

Psoriasis patients with no prior diagnosis of PsA randomized to receive intervention PsA questionnaire, including instructions to talk with their doctor about a referral to a rheumatologist

Group II: Intervention with Direct Access to RheumatologistExperimental Treatment1 Intervention

Psoriasis patients with no prior diagnosis of PsA randomized to receive intervention PsA questionnaire, including instructions on how to directly schedule a rheumatologic evaluation

Group III: ControlActive Control1 Intervention

Psoriasis patients with no prior diagnosis of PsA randomized to not receive an intervention PsA questionnaire

0 / 3Eligibility criteria met